---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009247"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:09:56.193340+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics stockholders elect Clancy and Rossi as Class III directors at annual meeting

## Summary
- Stockholders elected Paul J. Clancy and Christina Rossi as Class III directors each with ~94.4% of votes cast (excluding broker non-votes).
- Auditor Ernst & Young ratified with 26,199,617 votes for (99.6% of votes cast).
- Broker non-votes of 6,783,293 on director election; none on auditor ratification.

## SEC filing metadata
- accession: 0001558370-24-009247
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837024009247/0001558370-24-009247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837024009247/xlo-20240613x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009247
- JSON: https://secwatch.observer/filing/0001558370-24-009247.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009247.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.